A central scientific theme at Revolution Medicines is RAS ON inhibitor platform; Tri-Complex small molecule platform adds a second dimension to its role as a biopharmaceutical company. Revolution Medicines is also associated with active-state RAS targeting and KRAS mutant cancer therapeutics; pan-RAS pathway inhibition supplies another durable point of scientific differentiation. For Revolution Medicines, MAPK pathway cancer targeting is retained as a stable scientific attribute, while named products and targets remain separate entities.
MSD is putting $400 million upfront—and up to $1.73 billion more—on the line to license SciBrunch Therapeutics’ KRAS G12D inhibitor SPR2015. The move comes as Keytruda’s patent clock ticks down.
We use cookies to operate the website and understand site usage and improve your experience
